Katie Cook - Evolent Health Chief Officer
| EVH Stock | USD 11.13 0.21 1.85% |
Executive
Katie Cook is Chief Officer of Evolent Health
| Address | 1812 N. Moore Street, Arlington, VA, United States, 22209 |
| Phone | 571 389 6000 |
| Web | https://www.evolent.com |
Evolent Health Management Efficiency
The current Return On Tangible Assets is estimated to decrease to -0.15. The current Return On Capital Employed is estimated to decrease to -0.04. As of now, Evolent Health's Other Assets are increasing as compared to previous years. The Evolent Health's current Other Current Assets is estimated to increase to about 73.6 M, while Total Current Assets are projected to decrease to under 354.3 M. Evolent Health's management efficiency ratios could be used to measure how well Evolent Health manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Kevin Feeley | GeneDx Holdings Corp | 43 | |
| Sabrina Osborne | Humacyte | N/A | |
| Yang MD | Humacyte | 58 | |
| Paul MD | GeneDx Holdings Corp | N/A | |
| Feras Hantash | GeneDx Holdings Corp | N/A | |
| Harold Alterson | Humacyte | N/A | |
| Shamik MD | Humacyte | 51 | |
| Karen Ponchner | GeneDx Holdings Corp | N/A | |
| Heidi JD | GeneDx Holdings Corp | 57 | |
| Melanie Duquette | GeneDx Holdings Corp | N/A | |
| Jason Ryan | GeneDx Holdings Corp | 50 | |
| SPHR GPHR | Humacyte | N/A | |
| Eric Olivares | GeneDx Holdings Corp | N/A | |
| William Scheessele | Humacyte | 52 | |
| Jami Biliboaca | GeneDx Holdings Corp | N/A | |
| Britt Johnson | GeneDx Holdings Corp | N/A | |
| FACMG MD | GeneDx Holdings Corp | N/A | |
| Kevin CPA | GeneDx Holdings Corp | 43 | |
| Jerry Conway | GeneDx Holdings Corp | N/A | |
| Sabrina Dunbar | GeneDx Holdings Corp | N/A | |
| Jennifer Brendel | GeneDx Holdings Corp | N/A | |
Management Performance
| Return On Equity | -0.0578 | ||||
| Return On Asset | 0.0073 |
Evolent Health Leadership Team
Elected by the shareholders, the Evolent Health's board of directors comprises two types of representatives: Evolent Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evolent. The board's role is to monitor Evolent Health's management team and ensure that shareholders' interests are well served. Evolent Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evolent Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jonathan JD, General Officer | ||
| Thomas Peterson, Chief Operating Officer | ||
| Katie Cook, Chief Officer | ||
| Robert Cruz, Chief Officer | ||
| Dan McCarthy, CEO President | ||
| John MD, Chief Officer | ||
| Nicholas McGrane, Executive Vice President of Corporate Performance | ||
| Bridget Duffy, Independent Director | ||
| Tunde Sotunde, Independent Director | ||
| MAAA FSA, Chief Officer | ||
| Emily Rafferty, Chief Officer | ||
| Bruce Felt, Independent Director | ||
| John Johnson, Chief Financial Officer | ||
| M Duffy, Independent Director | ||
| Craig Barbarosh, Independent Director | ||
| Steve Tutewohl, Chief Operating Officer | ||
| Cheryl Scott, Lead Independent Director | ||
| Seth Blackley, Chief Executive Officer, Co-Founder, Director | ||
| Frank Williams, Co-Founder, CEO, Director and Chairman of Nominating and Governance Committee | ||
| Jonathan Weinberg, General Counsel | ||
| David Farner, Director | ||
| Aammaad Shams, Interim Principal Accounting Officer and Corporate Controller | ||
| Jessica Somers, Sr Devel | ||
| Seth Frank, Vice Relations | ||
| Mark Mannion, Senior Finance | ||
| Peter Grua, Independent Director | ||
| Diane Holder, Director | ||
| Michael DAmato, Independent Director | ||
| Kali Beyah, Chief Officer | ||
| Jessica White, Chief Officer | ||
| Kim Keck, Independent Director |
Evolent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Evolent Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0578 | ||||
| Return On Asset | 0.0073 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | (0.03) % | ||||
| Current Valuation | 1.84 B | ||||
| Shares Outstanding | 115.03 M | ||||
| Shares Owned By Insiders | 3.94 % | ||||
| Shares Owned By Institutions | 96.06 % | ||||
| Number Of Shares Shorted | 10.51 M | ||||
| Price To Earning | (13.88) X |
Currently Active Assets on Macroaxis
When determining whether Evolent Health offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evolent Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evolent Health Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evolent Health Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evolent Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For more detail on how to invest in Evolent Stock please use our How to Invest in Evolent Health guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evolent Health. If investors know Evolent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evolent Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.92) | Revenue Per Share 21.554 | Quarterly Revenue Growth 0.216 | Return On Assets 0.0073 | Return On Equity (0.06) |
The market value of Evolent Health is measured differently than its book value, which is the value of Evolent that is recorded on the company's balance sheet. Investors also form their own opinion of Evolent Health's value that differs from its market value or its book value, called intrinsic value, which is Evolent Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evolent Health's market value can be influenced by many factors that don't directly affect Evolent Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evolent Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evolent Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evolent Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.